Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) functions as a negative regulator of endogenous and vaccine-induced antitumor immunity. The administration of fully human anti-CTLA-4 blocking monoclonal antibodies to advanced-cancer patients increases immune-mediated tumor destruction in some subjects. Nonetheless, patients that respond also frequently manifest serious inflammatory pathologies, raising the possibility that the therapeutic and toxic effects of CTLA-4 blockade might be linked. Here we show that periodic infusions of anti-CTLA-4 antibodies after vaccination with irradiated, autologous tumor cells engineered to secrete GM-CSF (GVAX) generate clinically meaningful antitumor immunity without grade 3 or 4 toxicity in a majority of metastatic melanoma patients. The application of this sequential immunotherapy to advanced ovarian carcinoma patients also revealed that tumor destruction and severe inflammatory pathology could be dissociated, although further refinements are required to increase clinical responses and to minimize toxicity in this population. The extent of therapy-induced tumor necrosis was linearly related to the natural logarithm of the ratio of intratumoral CD8(+) effector T cells to FoxP3(+) regulatory T cells (Tregs) in posttreatment biopsies. Together, these findings help clarify the immunologic and clinical effects of CTLA-4 antibody blockade in previously vaccinated patients and raise the possibility that selective targeting of antitumor Tregs may constitute a complementary strategy for combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“First successes of immune therapy have proved that the patient's own immune system can be activated to destroy tumor cells [86][87][88][89][90][91][92].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [87]
In the citing paper
“Subsequent research on the correlates of response of anti-CTLA4 therapy demonstrated that the extent of ICTinduced tumor necrosis was directly related to the ratio of intratumoral CD8 T cells to FOXP3 + Tregs (148).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [148]
In the citing paper
“a higher ratio of effector CD8 + T cells to Tregs in the tumors of previously vaccinated patients with melanoma correlated favorably with tumor necrosis (155).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169 · cited 1×
“Notwithstanding this close relationship, cancer genome sequencing experiments have uncovered a multiplicity of mutated gene products that derive from defects in tumor cell DNA repair mechanisms (30, 31).”
BackgroundTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · cited 1×
“tial mediator of immune homeostasis, as illuminated by the fatal lymphoproliferative disorder that arises in young CTLA-4deficient mice (27, 28).”
BackgroundLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 1×
“tial mediator of immune homeostasis, as illuminated by the fatal lymphoproliferative disorder that arises in young CTLA-4deficient mice (27, 28).”
BackgroundSato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372 · cited 2×
“Although the antitumor response did not involve the generation of anti-CA-125 antibodies (data not shown), increased humoral reactions to NY-ESO-1, a cancer-testis antigen ectopically expressed in many ovarian carcinomas (26), were associated with therapeutic activity (Fig.”
BackgroundRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175 · cited 1×
“Future investigations of genetic polymorphisms and the complex patterns of alternative splicing in the CTLA-4 locus might help identify high-risk patients (19, 32), for whom even lower doses of antibody or alternative therapies could be contemplated.”
BackgroundImmunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702 · cited 1×
“One major defect involves inefficient antigen presentation by tumor-infiltrating dendritic cells and macrophages (2).”
BackgroundPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Self-citationCytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573 · cited 1×
“T frequently provoke innate and adaptive immune recognition, but the development of clinically evident disease denotes a failure of host defense (1).”
BackgroundSelf-citationvan Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Self-citationAttia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · cited 1×
“Together, these findings suggest that complementary strategies that target intratumoral Tregs might extend the clinical benefits of GVAX and CTLA-4 blockade (35).”
BackgroundSelf-citationHodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · cited 3×
“Consistent with this idea, we previously demonstrated that a single infusion of anti-CTLA-4 antibody (3 mg/kg of MDX-010, Ipilumimab) triggered striking tumor necrosis without severe toxicity in five of five metastatic melanoma or ovarian carcinoma patients who were previously immunized with GVAX (24).”
BackgroundSelf-citationComplexities of CD28/B7: CTLA-4 Costimulatory Pathways in Autoimmunity and Transplantation
Salomon, B., & Bluestone, J. A. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.225 · Cited by 1,006
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., DeBiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 988 · cited 1×
“Notwithstanding this close relationship, cancer genome sequencing experiments have uncovered a multiplicity of mutated gene products that derive from defects in tumor cell DNA repair mechanisms (30, 31).”
BackgroundSelf-citationSmyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870 · cited 1×
“Thus, although overall survival remains the most important parameter of clinical efficacy, the adoption of new indexes that incorporate recent insights into the concept of immune equilibrium should be strongly considered (34).”
BackgroundBeck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833
Self-citationQuezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 17×
“Together, these findings help clarify the immunologic and clinical effects of CTLA-4 antibody blockade in previously vaccinated patients and raise the possibility that selective targeting of antitumor Tregs may constitute a complementary strategy for combination therapy.”
BackgroundResultSelf-citationHUMAN T CELL RESPONSES AGAINST MELANOMA
Boon, T., Coulie, P. G., Eynde, B. J. V. D., & Bruggen, P. V. D. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090733 · Cited by 651 · cited 2×
“Indeed, because some molecularly defined cancer antigens are nonmutated differentiation proteins expressed in normal tissues (29), tumor immunity and autoreactivity may be tightly associated in particular contexts.”
BackgroundThe Emerging Role of CTLA-4 as an Immune Attenuator
Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 634
Self-citationRibas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591
Gilboa, E. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31205 · Cited by 588 · cited 1×
“Diverse vaccination strategies, however, may enhance the acquisition and processing of tumor antigens by dendritic cells and thereby engender protective immunity (3).”
BackgroundCheckpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570 · cited 3×
“In this context, a key role has emerged for cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) as a negative regulator of antitumor responses (5).”
BackgroundSelf-citationHurwitz, A. A., Foster, B. A., Kwon, E. D., Truong, T. N., Choi, E. M., Greenberg, N. M., Burg, M. B., & Allison, J. P. (2000) · PubMed · Cited by 460
Self-citationThe immune paradox of sarcoidosis and regulatory T cells
Miyara, M., Amoura, Z., Parizot, C., Badoual, C., Dorgham, K., Trad, S., Kambouchner, M., Valeyre, D., Chapelon-Abric, C., Debré, P., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050648 · Cited by 450 · cited 1×
“Substantial numbers of CD3 T cells and FoxP3 Tregs were also evident, consistent with a recent report highlighting the involvement of these lymphocyte subsets in sarcoidosis (25).”
ResultBlockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo
Read, S., Greenwald, R., Izcue, A., Robinson, N., Mandelbrot, D., Francisco, L., Sharpe, A. H., & Powrie, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4376 · Cited by 434 · cited 1×
“Although CTLA-4 may contribute to Treg-induced immune suppression in some settings (13, 14), the infusion of anti-CTLA-4 antibodies triggers an overall expansion of Treg numbers in tumor-bearing hosts, especially in regional lymph nodes (12).”
BackgroundSanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 434 · cited 1×
“Future investigations of genetic polymorphisms and the complex patterns of alternative splicing in the CTLA-4 locus might help identify high-risk patients (19, 32), for whom even lower doses of antibody or alternative therapies could be contemplated.”
BackgroundHurwitz, A. A., Yu, T. F.-Y., Leach, D. R., & Allison, J. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10067 · Cited by 378
Self-citationIntrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M., Yellin, M. J., Haworth, L. R., Levy, C., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 265
Jinushi, M., Nakazaki, Y., Dougan, M., Carrasco, D. R., Mihm, M., & Dranoff, G. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30966 · Cited by 195 · cited 1×
“In this context, we recently showed that GM-CSF promotes the development of FoxP3 Tregs during tumor vaccination through a pathway involving the milk fat globuleEGF protein 8 (MFG-E8)-mediated uptake of apoptotic cells by antigen-presenting cells (36).”
BackgroundSelf-citationMeasuring response in a post-RECIST world: from black and white to shades of grey
Michaelis, L. C., & Ratain, M. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1883 · Cited by 192 · cited 1×
“This profile of therapeutic activity is not adequately captured by the current RECIST criteria for monitoring tumor response, which primarily are based on target lesion volume (33).”
BackgroundJinushi, M., Hodi, F. S., & Dranoff, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603503103 · Cited by 168 · cited 2×
“These humoral reactions antagonized the immune suppression evoked by soluble MICA and augmented innate and adaptive antitumor cytotoxicity.”
BackgroundSelf-citationReuben, J. M., Lee, B., Li, C., Gomez‐Navarro, J., Bozon, V. A., Parker, C. A., Hernandez, I. M., Gutierrez, C., Lopez‐Berestein, G., & Camacho, L. H. (2006) · Cancer · doi:10.1002/cncr.21854 · Cited by 144 · cited 1×
“Although CTLA-4 may contribute to Treg-induced immune suppression in some settings (13, 14), the infusion of anti-CTLA-4 antibodies triggers an overall expansion of Treg numbers in tumor-bearing hosts, especially in regional lymph nodes (12).”
BackgroundAutoantibodies frequently detected in patients with aplastic anemia
Hirano, N., Butler, M. O., von Bergwelt-Baildon, M. S., Maecker, B., Schultze, J. L., O'Connor, K. C., Schur, P. H., Kojima, S., Guinan, E. C., & Nadler, L. M. (2003) · Blood · doi:10.1182/blood-2002-11-3409 · Cited by 113
Self-citationInduction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Restricts Clonal Expansion of Helper T Cells
Doyle, A. M., Mullen, A. C., Villarino, A. V., Hutchins, A. S., High, F. A., Lee, H. W., Thompson, C. B., & Reiner, S. L. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.7.893 · Cited by 102
Combinatorial Cancer Immunotherapy
Hodi, F. S., & Dranoff, G. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90009-1 · Cited by 56 · cited 2×
“This autologous tumor-cell-based vaccination strategy consistently enhances specific and long-lasting immunity, which likely encompasses at least some tumor-restricted epitopes (4).”
BackgroundSelf-citationCTLA-4 Blockade: Autoimmunity As Treatment
Kapadia, D., & Fong, L. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.012 · Cited by 36 · cited 1×
“Indeed, some current strategies for identifying the optimal dose and schedule of antibody treatment are based on the idea that tumor destruction might require a major breach of tolerance to normal self-antigens (22, 23).”
BackgroundCheckpoint blockade in cancer immunotherapy
Allison, J. P. (2007) · The biomedical & life sciences collection. · doi:10.69645/wrfi5863 · Cited by 16
Self-citationSelf-Recognition and Tumor Response to Immunotherapy
Ernstoff, M. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.95.029 · Cited by 7 · cited 1×
“Indeed, some current strategies for identifying the optimal dose and schedule of antibody treatment are based on the idea that tumor destruction might require a major breach of tolerance to normal self-antigens (22, 23).”
Background
Cited by
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citationCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Self-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Self-citationMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Metadata
- Authors
- Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., Korman, A., Lautz, D., Russell, S., Jaklitsch, M. T., Ramaiya, N., Chen, T. C., Neuberg, D., Allison, J. P., Mihm, M. C., & Dranoff, G.
- Affiliations
- Brigham and Women's Hospital (US)
- Fox Chase Cancer Center (US)
- Tufts Medical Center (US)
- Medarex, Inc., 67 Beaver Avenue, Annandale, NJ 08801;
- Harvard University (US)
- Massachusetts Eye and Ear Infirmary (US)
- Memorial Sloan Kettering Cancer Center (US)
- Departments of cPathology and
- Corresponding author
- Allison, James P.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-02-26
- Volume
- 105
- Issue
- 8
- Pages
- 3005-3010
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2268575
- OpenAlex
- W2155189639
- Cited by
- 650
- References
- 41
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 14 · 2023: 21 · 2022: 20 · 2021: 20 · 2020: 35 · 2019: 33 · 2018: 37 · 2017: 51 · 2016: 61 · 2015: 58 · 2014: 51 · 2013: 54 · 2012: 42
- FWCI
- 24.27
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R21CA105776, CA111506, CA105776, R01CA111506)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CTLA-4 blockade, anti-CTLA-4 monoclonal antibody, GVAX, autologous tumor cell vaccination, metastatic melanoma, ovarian carcinoma, regulatory T cells, Foxp3, CD8+ effector T cells, antitumor immunity, immune checkpoint inhibitors, tumor necrosis, GM-CSF
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antigens, Differentiation, Carcinoma, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunization, Passive, Melanoma, Ovarian Neoplasms, Cohort Studies, Antigens, CD, Granulocyte-Macrophage Colony-Stimulating Factor, T-Lymphocytes, Regulatory, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.